

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over ID6448

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

Stakeholders highlighted that:

- the burden of non-cystic fibrosis bronchiectasis varies across regions of England and may be influenced by socioeconomic status, which can affect access to diagnosis, specialist services, and new treatments
- there is significant variation in how people with chronic respiratory conditions are reviewed and managed across the UK. If prescribing is restricted narrowly in secondary care rather than broadly, this could lead to unequal access to brensocatib
- adults with paediatric-onset bronchiectasis may experience more severe disease over time. If access to brensocatib is restricted based on age, this group could be disproportionately disadvantaged

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|---|

The committee will consider health inequality evidence submitted during the course of the evaluation. It should also consider whether recommendations would make it harder for anyone to access brensocatib as a result of a protected characteristic.

With regards to age, the committee can only appraise a treatment within its marketing authorisation. It will consider if recommendations based on age

are appropriate, based on the clinical and cost effectiveness evidence presented, and take into account the potential inequalities issues around such recommendations, if relevant.

3. Has any change to the draft scope been agreed to highlight potential equality issues?
--

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
--

No

Approved by Associate Director: Emily Crowe

Date: 26/09/2025